SCHEMBL5287546

SCHEMBL5287546

COc1cccc(C(=O)Nc2ccc3c(c2)ncn3C(CC(=O)O)c2ccccc2)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2B P18089 4/20 0.47
KLKB1 P03952 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
KLK1 P06870 2/20 0.44
KLK5 Q9Y337 2/20 0.44
MAPT P10636 4/20 0.44
KDR P35968 1/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
HSD17B10 Q99714 3/20 0.43
TP53 P04637 2/20 0.43
PRNP P04156 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KCNK3 O14649 2/20 0.43
KCNK9 Q9NPC2 2/20 0.43
LMNA P02545 1/20 0.43
BRPF1 P55201 1/20 0.43
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5302849 0.93 KLKB1 (0.45) ADRA2BKLKB1SMN1; SMN2KLK1KLK5
SCHEMBL2297333 0.90 ADRA2B (0.49) ADRA2BSMN1; SMN2MAPTNPC1RAB9A
SCHEMBL2297485 0.88 KMT2A (0.47) SMN1; SMN2KLK1KLK5KDRNPC1
SCHEMBL2295353 0.86 RAB9A (0.45) SMN1; SMN2NPC1RAB9AHSD17B10TP53
SCHEMBL2295738 0.86 MEN1 (0.45) ADRA2BSMN1; SMN2MAPTNPC1RAB9A
SCHEMBL2296926 0.85 KMT2A (0.49) SMN1; SMN2MAPTNPC1RAB9AKCNK3
SCHEMBL2295816 0.84 RAB9A (0.45) SMN1; SMN2NPC1RAB9AHSD17B10TP53
SCHEMBL5292979 0.84 RAB9A (0.43) SMN1; SMN2MAPTNPC1RAB9AHSD17B10
SCHEMBL2298509 0.84 NR1H4 (0.47) SMN1; SMN2NPC1RAB9ALMNAMEN1
SCHEMBL2295817 0.83 FADS1 (0.46) SMN1; SMN2NPC1RAB9AHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828144-A2 INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS OSI Pharmaceuticals, Inc. (US) 2007-09-05 EP claimed
WO-2006053342-A2 INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS OSI PHARMACEUTICALS, INC. (US) 2006-05-18 WO claimed